ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2025
Exposure to androgen deprivation therapy and risk of anastomotic leakage after colorectal cancer surgery.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A risk prediction model for overall and Grade C anastomotic leakage after rectal cancer surgery.Frontiers in oncology · 2026Article
- Perioperative nonsteroidal anti-inflammatory drugs and the risk for anastomotic leakage in patients undergoing major gastrointestinal surgery: a retrospective cohort study.BMC anesthesiology · 2025Article
- Exposure to androgen deprivation therapy and risk of anastomotic leakage after colorectal cancer surgery.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimThe risk of anastomotic leakage after colorectal cancer surgery is higher in men, regardless of the anatomical location. Previous studies suggest that this might be due to hormonal differences. The aim of this work was to investigate whether androgen deprivation therapy influenced the incidence of anastomotic leakage.
methodThis is a nationwide registry-based study of men operated on between 2007 and 2021 for colorectal cancer with an anastomosis. Exposure to androgen deprivation therapy (prescribed drugs or surgical castration) was related to anastomotic leakage using mixed-effects logistic regression models. Two control groups were formed: one without and one with prostate cancer but without androgen deprivation. To study the potential target for androgen effect in intestinal tissue, androgen receptor expression was evaluated using immunohistochemistry in a smaller independent cohort to compare receptor expression in relation to leakage.
resultsSome 24 611 men were included in the registry study, of whom 2.4% were exposed to androgen deprivation therapy. In this exposed group, compared with unexposed men with and without prostate cancer, respectively, leak rates were 3.7%, 5.6% and 5.8%, respectively. After adjustment, a nonsignificant reduction of anastomotic leakage in the exposed group was detected (OR 0.70, 95% CI 0.45-1.09) compared with men without prostate cancer. Tissue expression of androgen receptor was very low among patients with and without leakage, albeit with a trend of higher expression among the latter.
conclusionAnastomotic leakage rates might be lower in men exposed to androgen deprivation therapy before surgery for colorectal cancer, although this finding must be interpreted cautiously. Effects on anastomotic healing do not seem to be mediated through classical androgen receptor signalling in the intestine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.